Pfizer Says ‘No Data’ To Support Single-Dose Vaccine Success After 21 Days

The world rejoiced when a pair of coronavirus vaccines were announced at the end of last year — a feat previously thought to have been unimaginable but made possible by President Trump’s Operation Warp Speed.

The vaccines were swiftly developed and tested — within months — then produced, and distributed to people across the United States and Europe.

All that is remaining is for people who need to or wish to take the vaccine to do so.

As Axios reports, the U.K. has a limited supply of the Pfizer vaccine and are quickly distributing single-doses of the vaccine to everyone who needs it: “to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible.”

The problem is: The Pfizer vaccine has a 2-dose requirement.

So, the U.K. is handing out all their doses to individuals rather than keeping the second-dose readily available for those who took the first dose.

The company pushed back on the strategy, admitting they had “no data” to support that the single-dose would aid in curing or preventing the coronavirus.

Axios reports:

  • Pfizer confirmed in response that although some protection appears to begin as early as 12 days after the first dose, two doses of the vaccine — separated by three weeks — is the only regimen that proved to be 95% effective in Phase 3 trials.
  • “Everyone will still receive their second dose and this will be within 12 weeks of their first,” the U.K. government added in a statement. “The second dose completes the course and is important for longer term protection.”

“Pfizer’s warning comes as many countries, including the U.S., debate how to rapidly deploy the vaccines in the most effective way possible,” the report adds. “The U.S. is on pace to fall far below its target of vaccinating 20 million people by the end of 2020, with only 3 million single-doses administered as of Wednesday night.”